An introduction to APN LifeSciences

APN LifeSciences, founded by Dr. Ming-Kuei Jang, is a company focused on advancing the development of novel positron emission tomography (PET) imaging agents, blood tests, and other related diagnostic technologies for neurogenerative disease such as Alzheimer's Disease and Parkinson's Disease. By integrating PET imaging systems with AI-based image recognition, the company aims to visualize brain abnormalities in patients with dementia, enabling clinicians to accurately differentiate disease types at early stages, assess disease severity, and predict treatment outcomes. 

APN LifeSciences is also planning to establish an early dementia screening and brain health management platform to make the diagnosis of neurodegenerative diseases more accessible and efficient, ultimately achieving real-time and personalized medical care. 

Dementia has become one of the most pressing global public health issues in the world today. According to 2019 data from Alzheimer's Disease International, one new case of dementia is diagnosed every three seconds worldwide. The World Health Organization (WHO) has also reported that by 2050, the number of dementia patients globally is projected to reach 132 million. In Taiwan, the National Health Research Institute estimates that approximately 8% of people aged 65 or older—around 350,000 individuals—suffer from dementia. The urgency of dementia prevention and care cannot be overstated. 

The fight against dementia should not fall solely on patients and their families—it requires the joint efforts of global biomedical researchers, governments, institutions, patients, and caregivers. APN LifeSciences aspires to collaborate with all stakeholders to build a dementia prevention ecosystem and a brain health platform that ensures no patient is left behind through early screening, early intervention, and precision care.